Amanda Greene, NP
Adult Health · Ridgeland, MSNPI 1083040562
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by EMD Serono, Inc. at 30.6% of the total. Reporting peaked in 2022 at $44,707 and has fallen 64.8% since, to $15,749 in 2025. Among adult health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,578 payments — averaging $68.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$33K
- Biogen$20K
- AstraZeneca$7K
- TG Therapeutics, Inc.$7K
- Amgen$6K
- Sanofi$5K
- plus $29K from 45 others
What the payments were for
- Consulting fees$10,89910%
- Speaking & faculty fees$45,14942%
- Travel & lodging$14,25213%
- Food & beverage$37,16734%
- Education$2690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,735 in reported general payments places this provider in the 95th percentile of 93 adult health providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 56 | $2,034,929 |
| CortrophinCorticotropin | 21 | $1,810,964 |
| TysabriNatalizumab | 168 | $1,394,594 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 39 | $324,252 |
| Kesimpta PenOfatumumab | 18 | $174,963 |
| VumerityDiroximel Fumarate | 13 | $114,474 |
| NuedextaDextromethorphan Hbr/Quinidine | 61 | $94,051 |
| AustedoDeutetrabenazine | 12 | $83,810 |
| RuxienceRituximab-Pvvr | 14 | $79,861 |
| Dalfampridine ErDalfampridine | 183 | $75,424 |
| RexultiBrexpiprazole | 28 | $71,924 |
| NuplazidPimavanserin Tartrate | 15 | $70,834 |
| Emgality PenGalcanezumab-Gnlm | 48 | $33,204 |
| FycompaPerampanel | 26 | $31,243 |
| UbrelvyUbrogepant | 20 | $30,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Ocrevus | $432 | $2,034,92956 claims |
| BiogenTysabri, Vumerity | $19,797 | $1,509,068181 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $2,246 | $94,05161 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,070 | $83,81012 claims |
| PfizerRuxience | $1,678 | $79,86114 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,277 | $71,92428 claims |
| AbbVieUbrelvy, Vraylar, Linzess, Restasis Multidose | $2,833 | $71,39865 claims |
| Acadia Pharmaceuticals IncNuplazid | $540 | $70,83415 claims |
| Eisai Inc.Fycompa | $609 | $31,24326 claims |
| Upsher-smith Laboratories LLCTopiramate | $19 | $54166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 adult health providers in Mississippi.
Other adult health in Ridgeland
- Rebecca McWhirterRidgeland$3K
- Joshua LedfordRidgeland$3K
- Stephanie FarriorRidgeland$2K
- Michelle HughesRidgeland$444
- Rhonda HickmanTupelo$15K
- Angela SlaterFlorence$14K
- Jennifer Delaney-DavisOcean Springs$9K
- Traci EvansGulfport$8K
- Casey AdamsGulfport$8K
- Keila BrownJackson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.